Tata India Pharma & Healthcare Fund Direct Growth

Very High Risk
Equity
Sector - Healthcare

NAV as on Dec 19, 2025

Price per unit of the scheme.

₹ 35.34100.89%1 Day Change

-1.82%

Minimum Investment₹5000

Expense Ratio0.97%

FUND RATING

A holistic measure of the rank of a fund relative to its peers. Top funds receive a score of 5.

*Morningstar Rating Methodology i

RISK-O-METER

Level of risk associated with a mutual fund to help investors make informed investment decisions

FUND PERFORMANCE

As On Jan 01, 2023

Compare fund’s performance against category average across different time periods

No Data Found.

Returns <= 1 year are absolute and > 1 year are annualised (CAGR)

For calculating Category Return & Scheme Ranking, only Growth & Direct schemes are considered.

FUND COMPARISON

1M 3M 6M 1Y 3Y 5Y

This Fund

Tata India Pharma & Healthcare Fund Direct Growth

Equity: Sector - Healthcare Average NAV

Topper in Equity: Sector - Healthcare

All Fund

No Data Found.

*For the other fund, rescaled NAVs are used

RETURN CALCULATOR

Check the return on your investment in the fund

Tata India Pharma & Healthcare Fund Direct Growth

Investment Type

Monthly Investment

Time Period (yrs)

Annual Return in %

Invested Amount
₹0
Return
₹0

Current Value
₹0

FUND SUMMARY

Benchmark

IISL Nifty Pharma TR INR

Expense Ratio

0.97%

Category Avg Expense Ratio

1.01%

Minimum Investment (Lumpsum/SIP)

₹ 5000 /₹ 1000

Lock In (Years)

No Lock-in

Fund Size

₹ 1,338.85 Cr(As on Nov, 2025)

Inception Date

Dec 28, 2015

Turnover

37.86 %

Exit Load

0.25% of NAV if redeemed on or before expiry of 30 days from the date of allotment.

Objective: The investment objective of the scheme is to seek long term capital appreciation by investing atleast 80% of its net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved.The Scheme does not assure or guarantee any returns.

Tata India Pharma & Healthcare Fund Direct Growth is an Equity - Sector - Healthcare fund. The fund was launched inDec 28, 2015. Its risk level is . The NAV of the fund as onDec 19, 2025 is ₹35.34. Its expense ratio is 0.97 %. The fund has an AUM of ₹1,338.85 Cr.The fund is managed byMeeta Shetty,Rajat Srivastava.
The minimum initial investment is ₹5000 in Lumpsum mode.

SUBSCRIBE TO

BUSINESS TODAY MAGAZINE

Subscribe Now

Already a subscriber?Login

FUND MANAGER

Meeta Shetty

Lead Fund Manager.

Mar 9, 2021 - Present

Fund Manager Rank4Out of 10
i
Rank measured on the basis of consistent alpha the fund manager delivered in the same category over a period of three years (factors only Direct plan, Growth option)
Schemes managed6
Total AUM₹ 27,419.19 Cr
Highest Return In 1 Yr1.98 %

Other Funds

table
card

Fund NameMorningstar RatingNAVFund ReturnCategory ReturnRiskFund Size

Tata Digital India Fund Direct Growth

₹ 57.92

2.90%

2.46%

Very High Risk

₹12,084.86Cr

Tata Focused Equity Fund Direct Growth

₹ 26.19

-0.40%

-0.94%

Very High Risk

₹1,881.41Cr

Tata Nifty India Digital ETF Fund of Fund Direct Growth

₹ 15.60

1.09%

2.46%

Very High Risk

₹133.81Cr

Tata Digital India Fund Direct Growth

Very High Risk--

NAV₹ 57.92
Fund Size₹12,084.86Cr

Fund Return2.90%

Category Return2.46%

Tata Focused Equity Fund Direct Growth

Very High Risk

NAV₹ 26.19
Fund Size₹1,881.41Cr

Fund Return-0.40%

Category Return-0.94%

Tata Nifty India Digital ETF Fund of Fund Direct Growth

Very High Risk--

NAV₹ 15.60
Fund Size₹133.81Cr

Fund Return1.09%

Category Return2.46%

Returns <= 1 year are absolute and > 1 year are annualised (CAGR)

Rajat Srivastava

Lead Fund Manager.

Sep 16, 2024 - Present

Schemes managed1
Total AUM₹ 1,338.85 Cr
Highest Return In 1 Yr-1.32 %

Other Funds

table
card

Fund NameMorningstar RatingNAVFund ReturnCategory ReturnRiskFund Size

Tata India Pharma & Healthcare Fund Direct Growth

₹ 35.34

-1.82%

-1.61%

Very High Risk

₹1,338.85Cr

Tata India Pharma & Healthcare Fund Direct Growth

Very High Risk--

NAV₹ 35.34
Fund Size₹1,338.85Cr

Fund Return-1.82%

Category Return-1.61%

Returns <= 1 year are absolute and > 1 year are annualised (CAGR)

DETAILED PORTFOLIO

As on Nov, 2025

EQUITY (94.98%)

DEBT (-%)

CASH (5.02%)

Allocation by Market Cap

Large Cap(36.52%)

Mid Cap(19.65%)

Small Cap(38.81%)

Industry Holdings

Drug Manufacturers Specialty Generic54.26%
Medical Care26.20%
Diagnostics Research12.13%
Agricultural Inputs4.36%
Drug Manufacturers Major1.73%
Medical Instruments Supplies1.32%

Stock Holdings

Sun Pharmaceuticals Industries Ltd7.75%
Max Healthcare Institute Ltd Ordinary Shares5.65%
HealthCare Global Enterprises Ltd5.13%
Abbott India Ltd5.04%
Apollo Hospitals Enterprise Ltd4.85%
Ipca Laboratories Ltd3.99%

PERFORMANCE MEASURES

Fund evaluation across critical parameters for better decision making. Study period is 3 years.

Consistency
i
It represents the consistency of a fund in beating its benchmark.
Downside Risk
i
Measured by Maximum Drawdown which shows the maximum loss from a peak to a nadir over a specified time period
Risk Adjusted Return
i
Risk adjusted return represents the return generated after factoring the risk taken to achieve it.
Volatility
i
Volatility represents the standard deviation of fund returns that is, how much the fund returns have deviated from the average.
Upside Capture Ratio
i
Fund performance relative to the index when the market is up. An upside capture ratio of >100 indicates better fund performance.
Downside Capture Ratio
i
Fund performance relative to the index when the market is down. A downside capture ratio of <100 indicates better fund performance.

HISTORICAL RISK MEASURES

Statistical measures to evaluate mutual fund risk. All ratios are calculated for a three-year time duration.

Alpha: Excess return of the fund over benchmark
i
Any Alpha above zero is considered good. However, for comparison, a fund with a higher Alpha is considered better. Alpha is normally used in conjunction with Beta. If the Beta is high, it implies that the fund manager took a high risk to generate Alpha.
0.48
This Fund
VS
-0.23
Category Avg
R-Squared: How well the fund tracks benchmark
i
R-Squared measures the correlation of fund returns and its benchmark returns. It varies between 0 and 1. The metric, Beta makes no sense if R-Squared is equal to zero. Thus, both Beta and R-Squared should be used in conjunction. A fund with a high R-Squared and low Beta is considered a less risky fund.
97.22
This Fund
VS
94.61
Category Avg

Beta: Risk of the fund in relation to benchmark
i
Beta >1 indicates that the fund is more volatile than its benchmark while Beta < 1 indicates that the fund is less volatile than its benchmark. The Beta of the benchmark is equal to 1.
0.98
This Fund
VS
0.96
Category Avg
Sharpe Ratio: Risk adjusted return of the fund
i
Sharpe Ratio is a measure of return per unit of risk. A higher Sharpe ratio indicates better risk adjusted return given by the fund.
1.00
This Fund
VS
0.94
Category Avg

Sortino Ratio: Return per unit of bad risk
i
A variation of Sharpe ratio, Sortino considers only the downside risk. Unlike Sharpe ratio which considers both good risk and bad risk, Sortino factors only the bad risk. A high Sortino ratio indicates better return for each unit of downside risk.
1.80
This Fund
VS
1.69
Category Avg
Standard Devation: Volatility of the fund
i
Standard deviation is a measure of dispersion of fund returns from its average return. A fund with a higher Standard deviation is more volatile than a fund with a low standard deviation.
16.06
This Fund
VS
16.00
Category Avg

Benchmark used in calculation : S&P BSE 500 India TR INR

PEER ANALYSIS

card
table

Fund NameMorningstar RatingNAV Fund Return Category ReturnRisk Fund Size

Returns <= 1 year are absolute and > 1 year are annualised (CAGR)

TOP FUNDS FROM THIS AMC

card
table

Fund NameMorningstar RatingNAV Fund Return Category Return Risk Fund Size (Cr)

Returns <= 1 year are absolute and > 1 year are annualised (CAGR)

ABOUT THE AMC

Tata Asset Management Pvt Ltd

Tata Asset Management Pvt Ltd manages assets worth ₹ 2,25,152.95 crores. It’s current offering of mutual fund schemes includes 38 equity, 18 debt and 10 hybrid schemes.

Phone

+91 22 6657 8282

kiran@tataamc.com

AUM

₹ 2,25,152.95 Cr (

As on Nov 30, 2025

)

Address

Mafatlal Centre, 9th Floor, Mumbai,400 021

FAQ's

What is the category of Tata India Pharma & Healthcare Fund Direct Growth ?

The category of Tata India Pharma & Healthcare Fund Direct Growth is Equity - Sector - Healthcare

What is the current NAV of Tata India Pharma & Healthcare Fund Direct Growth ?

The current NAV of Tata India Pharma & Healthcare Fund Direct Growth as on Dec 19, 2025 is ₹35.34

How safe is Tata India Pharma & Healthcare Fund Direct Growth ?

The risk level of Tata India Pharma & Healthcare Fund Direct Growth is Very High.

What are short term returns given by Tata India Pharma & Healthcare Fund Direct Growth ?

The return given by Tata India Pharma & Healthcare Fund Direct Growth in 1 month is -1.82%, 3 months is -3.16%, 6 months is 3.77%, and 1 year is -1.32%

What are the long term returns given by Tata India Pharma & Healthcare Fund Direct Growth ?

The return given by Tata India Pharma & Healthcare Fund Direct Growth in 3 years is 23.83% and 5 years is 16.89%.

What is the expense ratio of Tata India Pharma & Healthcare Fund Direct Growth ?

The expense ratio of Tata India Pharma & Healthcare Fund Direct Growth is 0.97%

What is the AUM of Tata India Pharma & Healthcare Fund Direct Growth ?

The assets under Management (AUM) of Tata India Pharma & Healthcare Fund Direct Growth is Rs 1,338.85 crores.

What is the minimum investment in Tata India Pharma & Healthcare Fund Direct Growth ?

The minimum Lumpsum investment in Tata India Pharma & Healthcare Fund Direct Growth is ₹5,000.00 and the minimum SIP investment in Tata India Pharma & Healthcare Fund Direct Growth is ₹1,000.00

What is the asset allocation of Tata India Pharma & Healthcare Fund Direct Growth?

Tata India Pharma & Healthcare Fund Direct Growth has an exposure of 94.98% in Equity and 5.02% in Cash & Money Market Securities